This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Bersani, F. S., Minichino, A., Enticott, P. G., Mazzarini, L., Khan, N., Antonacci, G., & Biondi, M. (2013). European Psychiatry, 28(1), 30-39.
This paper reviews the work done so far using the Brainsway® Deep TMS (Deep Transcranial Magnetic Stimulation) H-coil, and demonstrates the biological and physical components that participate in the effects generated by Deep Transcranial Magnetic Stimulation; both in general terms and for specific psychiatry disorders.